Dr. Xie Dejian is the co-founder and chief operating officer of xilingyuan Pharmaceutical Co., Ltd., and the general manager of kelingyuan Pharmaceutical Technology Co., Ltd. Before the establishment of xilingyuan, Dr. Xie served as vice president of Shanghai wisdom Chemical Research Co., Ltd., general manager of Shanghai Pioneer Chemical Research Co., Ltd. and general manager of Chengdu wisdom Chemical Research Co., Ltd., accumulating rich experience in technology development, enterprise management, business development and customer management. Before joining smart Chem, Dr. Xie Dejian worked at the Albany molecular research company (aMRI), focusing on the design and synthesis of drug molecules. He has accumulated rich experience in the research and development of innovative drugs in the fields of central nervous system, cancer and inflammation. Dr. Xie was the director of Chemistry Department of aMRI Singapore R & D center and one of the founders of the R & D center. Dr. Xie Dejian studied in Xiamen University, obtained his doctorate from Texas Christian University, and then engaged in post doctoral research at Washington University in St. Louis.
Senior vice president, drug development
Dr. Pete guzzo is the senior vice president of drug development of Chengdu kelingyuan Pharmaceutical Technology (a wholly-owned subsidiary of xilingyuan Pharmaceutical Co., Ltd.), mainly responsible for the work related to the company's innovative drug projects. Dr. guzzo is a senior pharmaceutical chemist with more than 20 years of experience in drug discovery and clinical phase I / II research. Dr. guzzo was the CEO of consynance therapeutics, Inc., and led the development of innovative drug projects in three clinical phases. Prior to that, Dr. guzzo served as the director of innovative drug development at Albany molecular research company (aMRI), leading the aMRI interdisciplinary drug research and development team, and developed 11 new molecules for clinical trials. Dr. Peter guzzo, Ph.D., graduated from the University of Notre Dame in the United States, and was engaged in post doctoral research at Rensselaer Polytechnic Institute.
Vice president of Biology
Dr. Kevin McLure has more than 20 years of research and development experience in the fields of new drug discovery and transformation biology, oncology, immunology and cardiovascular field. He has successively served as resollogix Corp. and zenith epigenetics in Canada, vitrisa therapeutics and ermaris in the United States Bio's director of biology and translational medicine has accumulated rich successful experience in target research and selection, drug development pathway and early clinical design. Dr. McLure served as the scientific consultant of Spark Program of Stanford University Medical School, and played a key role in the transformation of R & D achievements into commercial technology company projects. Dr. McLure graduated from the University of Calgary in Canada in 1998, and then worked in St. Jude Children's research hospital in Memphis for six years.
Chemical process director
Dr. Wu Chenglong is the chemical process director of xilingyuan Pharmaceutical Co., Ltd., responsible for the process development and application of API. Dr. Wu once served as the deputy director of the Chemical Department of Hengrui pharmaceutical Chengdu R & D Center (Shengdi pharmaceutical). He devoted himself to the research of pharmaceutical production process and crystallography, and led the process development and application of several APIs. Dr. Wu received his doctorate and master's degrees from West China College of Sichuan University.
Director of pharmaceutical chemistry
Dr. Chen Fang is the director of pharmaceutical chemistry of Chengdu kelingyuan Pharmaceutical (a wholly-owned subsidiary of xilingyuan Pharmaceutical Co., Ltd.), and is responsible for the pharmaceutical and chemical work of the company's innovative drug project. Dr. Chen has more than ten years of experience in the research and development of innovative drugs and generic drugs. As the principal person in charge of pharmaceutics, Dr. Chen has completed preclinical research on several innovative drugs, including Shanghai scientific research projects and national major projects (major new drug creation). Dr. Chen focuses on the design, synthesis and structure-activity relationship of small molecule drugs, and is familiar with the whole process of drug development. He has led several generic drug projects through CDE review and obtained approval. Dr. Chen Fang received a bachelor's degree from Sichuan University and a doctor's degree from Shanghai Institute of medicine, Chinese Academy of Sciences.
Ms. Gao Liyan is currently the commercial director of xilingyuan Pharmaceutical Co., Ltd., mainly responsible for the foreign cooperation and exchange of the company's projects. Ms. Gao Liyan once served as the BD and project director of Chengdu Dikang Pharmaceutical Co., Ltd., and quickly realized the establishment of BD team from scratch, and led to complete the introduction and cooperation of several generic drug projects, clarified the direction and field of the company's R & D pipeline layout, and laid a good foundation for the orderly development of BD and project approval. Ms. Li has been a senior manager in the field of biomedical research and cooperation with more than 200 pharmaceutical companies in Sichuan. At present, some products have been sold on the market and made profits. Ms. Gao Liyan obtained her bachelor's degree and master's degree from Sichuan University.
Director of operations
Ms. Li Xiaoxia is the chief operating officer of xilingyuan Pharmaceutical Co., Ltd. she is mainly responsible for the company's operation related work, including general manager's office, government related affairs and laboratory management. Ms. Li Xiaoxia has 12 years of experience in drug research and development. She has worked in Shanghai huilun, Chengdu Shengdi (a subsidiary of Jiangsu Hengrui) and Shanghai yaomingkangde. She has rich experience in drug application and registration, preclinical pharmacology and toxicology research and team management. Ms. Li Xiaoxia graduated from Shaanxi Normal University and graduated from CEIBS Mini MBA in 2016.
Technical director of catalytic center
Dr. Xu Zhiming is currently the technical director of xilingyuan pharmaceutical catalysis center. He is responsible for the screening and development of catalysts and their application in pharmaceutical process development and industrial production. Dr. Xu received a doctorate from Dartmouth College, a famous Ivy League institution. During his study and work in Dartmouth College, Dr. Xu successfully explored and published the world's first research achievement on the selective synthesis of a new C3 symmetric chiral phosphorus ligand under platinum metal catalysis; synthesized a new chiral phosphorus chelate with a new chelate shape and prepared corresponding nickel metal catalyst for the synthesis of chiral P-C bond; explored and published the research on platinum metal catalysis for the synthesis of chiral phosphorus carbon bond The effect of carbon chain length between two chiral phosphorus functional groups on the selectivity of chiral phosphorus ligands was studied. The selectivity and related mechanism of chiral catalysts were predicted by using the reaction data of cheap and easily available chiral ligands and their corresponding platinum metal catalysts.
Assistant director of analysis
Mr. Wang Min is the assistant director of analysis of xilingyuan Pharmaceutical Co., Ltd., responsible for organizing the quality research of the company's projects. Mr. Wang Min has been deeply engaged in the field of generic drug quality research for more than 10 years, and has rich team management and practical experience. Mr. Wang Min was the director of analysis project of Yangzi River Sichuan Hairong Pharmaceutical Co., Ltd. he was in charge of the quality research of many consistency evaluation projects and non conformance evaluation projects. Prior to that, Mr. Wang Min served as the director of the National Institute of pharmaceutical science and technology quality standards, directly responsible for and led the team to successfully complete the quality research of several generic drug projects (raw materials and preparations). Mr. Wang Min graduated from Chengdu University of traditional Chinese medicine.
Business Affairs：email@example.comContact us